APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Plasma-derived Hyperimmune Product

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Human Plasma-derived Hyperimmune Product Market Analysis and Forecast 2026-2032

21 December 2025191 pages

Choose your research edition.

Industry ResearchHuman Plasma-derived Hyperimmune Product Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Plasma-derived Hyperimmune Product Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Human Plasma-derived Hyperimmune Product Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Plasma-derived Hyperimmune Product Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Plasma-derived Hyperimmune Product Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Human Plasma-derived Hyperimmune Product market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Human Plasma-derived Hyperimmune Product is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Human Plasma-derived Hyperimmune Product is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Human Plasma-derived Hyperimmune Product is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Human Plasma-derived Hyperimmune Product is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Human Plasma-derived Hyperimmune Product include Sichuan Yuanda Shuyang, Shanghai RAAS, Grifols, Hualan Bio, Kedrion, Kamada, Emergent (Cangene), CSL Behring and CNBG, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Human Plasma-derived Hyperimmune Product, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Human Plasma-derived Hyperimmune Product, also provides the sales of main regions and countries. Of the upcoming market potential for Human Plasma-derived Hyperimmune Product, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Plasma-derived Hyperimmune Product sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Human Plasma-derived Hyperimmune Product market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Human Plasma-derived Hyperimmune Product sales, projected growth trends, production technology, application and end-user industry.

Human Plasma-derived Hyperimmune Product Segment by Company

Sichuan Yuanda Shuyang

Shanghai RAAS

Grifols

Hualan Bio

Kedrion

Kamada

Emergent (Cangene)

CSL Behring

CNBG

CBPO

Biotest

ADMA Biologics

Human Plasma-derived Hyperimmune Product Segment by Type

Rho(D) Immunoglobulins

Rabies Immunoglobulins

Tetanus Immunoglobulins

Hepatitis B Immunoglobulins

Other

Human Plasma-derived Hyperimmune Product Segment by Application

Government Institution

Private Sector

Others

Human Plasma-derived Hyperimmune Product Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Plasma-derived Hyperimmune Product market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Plasma-derived Hyperimmune Product and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Plasma-derived Hyperimmune Product.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Human Plasma-derived Hyperimmune Product in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Human Plasma-derived Hyperimmune Product manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Plasma-derived Hyperimmune Product sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Human Plasma-derived Hyperimmune Product Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Rho(D) Immunoglobulins Major Manufacturers Table 3. Rabies Immunoglobulins Major Manufacturers Table 4. Tetanus Immunoglobulins Major Manufacturers Table 5. Hepatitis B Immunoglobulins Major Manufacturers Table 6. Other Major Manufacturers Table 7. Global Human Plasma-derived Hyperimmune Product Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Government Institution Major Manufacturers Table 9. Private Sector Major Manufacturers Table 10. Others Major Manufacturers Table 11. Human Plasma-derived Hyperimmune Product Industry Trends Table 12. Human Plasma-derived Hyperimmune Product Industry Drivers Table 13. Human Plasma-derived Hyperimmune Product Industry Opportunities and Challenges Table 14. Human Plasma-derived Hyperimmune Product Industry Restraints Table 15. Global Human Plasma-derived Hyperimmune Product Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Human Plasma-derived Hyperimmune Product Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Human Plasma-derived Hyperimmune Product Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Region (2021-2026) Table 19. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Region (2027-2032) Table 20. Global Human Plasma-derived Hyperimmune Product Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 21. Global Human Plasma-derived Hyperimmune Product Sales by Region (2021-2026) & (k units) Table 22. Global Human Plasma-derived Hyperimmune Product Sales by Region (2027-2032) & (k units) Table 23. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Region (2021-2026) Table 24. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Region (2027-2032) Table 25. Global Human Plasma-derived Hyperimmune Product Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Human Plasma-derived Hyperimmune Product Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Manufacturers (2021-2026) Table 29. Global Human Plasma-derived Hyperimmune Product Sales Price (US$/unit) of Manufacturers (2021-2026) Table 30. Global Human Plasma-derived Hyperimmune Product Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Human Plasma-derived Hyperimmune Product Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Human Plasma-derived Hyperimmune Product Manufacturers, Product Type & Application Table 33. Global Human Plasma-derived Hyperimmune Product Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Human Plasma-derived Hyperimmune Product by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Human Plasma-derived Hyperimmune Product Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Human Plasma-derived Hyperimmune Product Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Human Plasma-derived Hyperimmune Product Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Type (2021-2026) Table 40. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Type (2027-2032) Table 41. Global Human Plasma-derived Hyperimmune Product Sales by Type 2021 VS 2025 VS 2032 (k units) Table 42. Global Human Plasma-derived Hyperimmune Product Sales by Type (2021-2026) & (k units) Table 43. Global Human Plasma-derived Hyperimmune Product Sales by Type (2027-2032) & (k units) Table 44. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2021-2026) Table 45. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2027-2032) Table 46. Global Human Plasma-derived Hyperimmune Product Price by Type (2021-2026) & (US$/unit) Table 47. Global Human Plasma-derived Hyperimmune Product Price by Type (2027-2032) & (US$/unit) Table 48. Global Human Plasma-derived Hyperimmune Product Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Human Plasma-derived Hyperimmune Product Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Human Plasma-derived Hyperimmune Product Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Application (2021-2026) Table 52. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Application (2027-2032) Table 53. Global Human Plasma-derived Hyperimmune Product Sales by Application 2021 VS 2025 VS 2032 (k units) Table 54. Global Human Plasma-derived Hyperimmune Product Sales by Application (2021-2026) & (k units) Table 55. Global Human Plasma-derived Hyperimmune Product Sales by Application (2027-2032) & (k units) Table 56. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2021-2026) Table 57. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2027-2032) Table 58. Global Human Plasma-derived Hyperimmune Product Price by Application (2021-2026) & (US$/unit) Table 59. Global Human Plasma-derived Hyperimmune Product Price by Application (2027-2032) & (US$/unit) Table 60. Sichuan Yuanda Shuyang Company Information Table 61. Sichuan Yuanda Shuyang Business Overview Table 62. Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 63. Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product Portfolio Table 64. Sichuan Yuanda Shuyang Recent Development Table 65. Shanghai RAAS Company Information Table 66. Shanghai RAAS Business Overview Table 67. Shanghai RAAS Human Plasma-derived Hyperimmune Product Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Shanghai RAAS Human Plasma-derived Hyperimmune Product Product Portfolio Table 69. Shanghai RAAS Recent Development Table 70. Grifols Company Information Table 71. Grifols Business Overview Table 72. Grifols Human Plasma-derived Hyperimmune Product Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Grifols Human Plasma-derived Hyperimmune Product Product Portfolio Table 74. Grifols Recent Development Table 75. Hualan Bio Company Information Table 76. Hualan Bio Business Overview Table 77. Hualan Bio Human Plasma-derived Hyperimmune Product Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Hualan Bio Human Plasma-derived Hyperimmune Product Product Portfolio Table 79. Hualan Bio Recent Development Table 80. Kedrion Company Information Table 81. Kedrion Business Overview Table 82. Kedrion Human Plasma-derived Hyperimmune Product Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Kedrion Human Plasma-derived Hyperimmune Product Product Portfolio Table 84. Kedrion Recent Development Table 85. Kamada Company Information Table 86. Kamada Business Overview Table 87. Kamada Human Plasma-derived Hyperimmune Product Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Kamada Human Plasma-derived Hyperimmune Product Product Portfolio Table 89. Kamada Recent Development Table 90. Emergent (Cangene) Company Information Table 91. Emergent (Cangene) Business Overview Table 92. Emergent (Cangene) Human Plasma-derived Hyperimmune Product Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product Portfolio Table 94. Emergent (Cangene) Recent Development Table 95. CSL Behring Company Information Table 96. CSL Behring Business Overview Table 97. CSL Behring Human Plasma-derived Hyperimmune Product Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. CSL Behring Human Plasma-derived Hyperimmune Product Product Portfolio Table 99. CSL Behring Recent Development Table 100. CNBG Company Information Table 101. CNBG Business Overview Table 102. CNBG Human Plasma-derived Hyperimmune Product Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. CNBG Human Plasma-derived Hyperimmune Product Product Portfolio Table 104. CNBG Recent Development Table 105. CBPO Company Information Table 106. CBPO Business Overview Table 107. CBPO Human Plasma-derived Hyperimmune Product Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. CBPO Human Plasma-derived Hyperimmune Product Product Portfolio Table 109. CBPO Recent Development Table 110. Biotest Company Information Table 111. Biotest Business Overview Table 112. Biotest Human Plasma-derived Hyperimmune Product Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Biotest Human Plasma-derived Hyperimmune Product Product Portfolio Table 114. Biotest Recent Development Table 115. ADMA Biologics Company Information Table 116. ADMA Biologics Business Overview Table 117. ADMA Biologics Human Plasma-derived Hyperimmune Product Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. ADMA Biologics Human Plasma-derived Hyperimmune Product Product Portfolio Table 119. ADMA Biologics Recent Development Table 120. North America Human Plasma-derived Hyperimmune Product Revenue by Type (2021-2026) & (US$ Million) Table 121. North America Human Plasma-derived Hyperimmune Product Revenue by Type (2027-2032) & (US$ Million) Table 122. North America Human Plasma-derived Hyperimmune Product Sales by Type (2021-2026) & (k units) Table 123. North America Human Plasma-derived Hyperimmune Product Sales by Type (2027-2032) & (k units) Table 124. North America Human Plasma-derived Hyperimmune Product Sales Price by Type (2021-2026) & (US$/unit) Table 125. North America Human Plasma-derived Hyperimmune Product Sales Price by Type (2027-2032) & (US$/unit) Table 126. North America Human Plasma-derived Hyperimmune Product Revenue by Application (2021-2026) & (US$ Million) Table 127. North America Human Plasma-derived Hyperimmune Product Revenue by Application (2027-2032) & (US$ Million) Table 128. North America Human Plasma-derived Hyperimmune Product Sales by Application (2021-2026) & (k units) Table 129. North America Human Plasma-derived Hyperimmune Product Sales by Application (2027-2032) & (k units) Table 130. North America Human Plasma-derived Hyperimmune Product Sales Price by Application (2021-2026) & (US$/unit) Table 131. North America Human Plasma-derived Hyperimmune Product Sales Price by Application (2027-2032) & (US$/unit) Table 132. North America Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. North America Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 134. North America Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 135. North America Human Plasma-derived Hyperimmune Product Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 136. North America Human Plasma-derived Hyperimmune Product Sales by Country (2021-2026) & (k units) Table 137. North America Human Plasma-derived Hyperimmune Product Sales by Country (2027-2032) & (k units) Table 138. North America Human Plasma-derived Hyperimmune Product Sales Price by Country (2021-2026) & (US$/unit) Table 139. North America Human Plasma-derived Hyperimmune Product Sales Price by Country (2027-2032) & (US$/unit) Table 140. United States Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 141. Canada Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 142. Mexico Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 143. Europe Human Plasma-derived Hyperimmune Product Revenue by Type (2021-2026) & (US$ Million) Table 144. Europe Human Plasma-derived Hyperimmune Product Revenue by Type (2027-2032) & (US$ Million) Table 145. Europe Human Plasma-derived Hyperimmune Product Sales by Type (2021-2026) & (k units) Table 146. Europe Human Plasma-derived Hyperimmune Product Sales by Type (2027-2032) & (k units) Table 147. Europe Human Plasma-derived Hyperimmune Product Sales Price by Type (2021-2026) & (US$/unit) Table 148. Europe Human Plasma-derived Hyperimmune Product Sales Price by Type (2027-2032) & (US$/unit) Table 149. Europe Human Plasma-derived Hyperimmune Product Revenue by Application (2021-2026) & (US$ Million) Table 150. Europe Human Plasma-derived Hyperimmune Product Revenue by Application (2027-2032) & (US$ Million) Table 151. Europe Human Plasma-derived Hyperimmune Product Sales by Application (2021-2026) & (k units) Table 152. Europe Human Plasma-derived Hyperimmune Product Sales by Application (2027-2032) & (k units) Table 153. Europe Human Plasma-derived Hyperimmune Product Sales Price by Application (2021-2026) & (US$/unit) Table 154. Europe Human Plasma-derived Hyperimmune Product Sales Price by Application (2027-2032) & (US$/unit) Table 155. Europe Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 156. Europe Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 157. Europe Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 158. Europe Human Plasma-derived Hyperimmune Product Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 159. Europe Human Plasma-derived Hyperimmune Product Sales by Country (2021-2026) & (k units) Table 160. Europe Human Plasma-derived Hyperimmune Product Sales by Country (2027-2032) & (k units) Table 161. Europe Human Plasma-derived Hyperimmune Product Sales Price by Country (2021-2026) & (US$/unit) Table 162. Europe Human Plasma-derived Hyperimmune Product Sales Price by Country (2027-2032) & (US$/unit) Table 163. Germany Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 164. France Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 165. U.K. Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 166. Italy Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 167. Russia Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 168. Spain Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 169. Netherlands Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 170. Switzerland Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 171. Sweden Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 172. Poland Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 173. China Human Plasma-derived Hyperimmune Product Revenue by Type (2021-2026) & (US$ Million) Table 174. China Human Plasma-derived Hyperimmune Product Revenue by Type (2027-2032) & (US$ Million) Table 175. China Human Plasma-derived Hyperimmune Product Sales by Type (2021-2026) & (k units) Table 176. China Human Plasma-derived Hyperimmune Product Sales by Type (2027-2032) & (k units) Table 177. China Human Plasma-derived Hyperimmune Product Sales Price by Type (2021-2026) & (US$/unit) Table 178. China Human Plasma-derived Hyperimmune Product Sales Price by Type (2027-2032) & (US$/unit) Table 179. China Human Plasma-derived Hyperimmune Product Revenue by Application (2021-2026) & (US$ Million) Table 180. China Human Plasma-derived Hyperimmune Product Revenue by Application (2027-2032) & (US$ Million) Table 181. China Human Plasma-derived Hyperimmune Product Sales by Application (2021-2026) & (k units) Table 182. China Human Plasma-derived Hyperimmune Product Sales by Application (2027-2032) & (k units) Table 183. China Human Plasma-derived Hyperimmune Product Sales Price by Application (2021-2026) & (US$/unit) Table 184. China Human Plasma-derived Hyperimmune Product Sales Price by Application (2027-2032) & (US$/unit) Table 185. Asia Human Plasma-derived Hyperimmune Product Revenue by Type (2021-2026) & (US$ Million) Table 186. Asia Human Plasma-derived Hyperimmune Product Revenue by Type (2027-2032) & (US$ Million) Table 187. Asia Human Plasma-derived Hyperimmune Product Sales by Type (2021-2026) & (k units) Table 188. Asia Human Plasma-derived Hyperimmune Product Sales by Type (2027-2032) & (k units) Table 189. Asia Human Plasma-derived Hyperimmune Product Sales Price by Type (2021-2026) & (US$/unit) Table 190. Asia Human Plasma-derived Hyperimmune Product Sales Price by Type (2027-2032) & (US$/unit) Table 191. Asia Human Plasma-derived Hyperimmune Product Revenue by Application (2021-2026) & (US$ Million) Table 192. Asia Human Plasma-derived Hyperimmune Product Revenue by Application (2027-2032) & (US$ Million) Table 193. Asia Human Plasma-derived Hyperimmune Product Sales by Application (2021-2026) & (k units) Table 194. Asia Human Plasma-derived Hyperimmune Product Sales by Application (2027-2032) & (k units) Table 195. Asia Human Plasma-derived Hyperimmune Product Sales Price by Application (2021-2026) & (US$/unit) Table 196. Asia Human Plasma-derived Hyperimmune Product Sales Price by Application (2027-2032) & (US$/unit) Table 197. Asia Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 198. Asia Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 199. Asia Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 200. Asia Human Plasma-derived Hyperimmune Product Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 201. Asia Human Plasma-derived Hyperimmune Product Sales by Country (2021-2026) & (k units) Table 202. Asia Human Plasma-derived Hyperimmune Product Sales by Country (2027-2032) & (k units) Table 203. Asia Human Plasma-derived Hyperimmune Product Sales Price by Country (2021-2026) & (US$/unit) Table 204. Asia Human Plasma-derived Hyperimmune Product Sales Price by Country (2027-2032) & (US$/unit) Table 205. Japan Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 206. South Korea Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 207. India Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 208. Australia Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 209. Taiwan Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 210. Southeast Asia Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 211. SAMEA Human Plasma-derived Hyperimmune Product Revenue by Type (2021-2026) & (US$ Million) Table 212. SAMEA Human Plasma-derived Hyperimmune Product Revenue by Type (2027-2032) & (US$ Million) Table 213. SAMEA Human Plasma-derived Hyperimmune Product Sales by Type (2021-2026) & (k units) Table 214. SAMEA Human Plasma-derived Hyperimmune Product Sales by Type (2027-2032) & (k units) Table 215. SAMEA Human Plasma-derived Hyperimmune Product Sales Price by Type (2021-2026) & (US$/unit) Table 216. SAMEA Human Plasma-derived Hyperimmune Product Sales Price by Type (2027-2032) & (US$/unit) Table 217. SAMEA Human Plasma-derived Hyperimmune Product Revenue by Application (2021-2026) & (US$ Million) Table 218. SAMEA Human Plasma-derived Hyperimmune Product Revenue by Application (2027-2032) & (US$ Million) Table 219. SAMEA Human Plasma-derived Hyperimmune Product Sales by Application (2021-2026) & (k units) Table 220. SAMEA Human Plasma-derived Hyperimmune Product Sales by Application (2027-2032) & (k units) Table 221. SAMEA Human Plasma-derived Hyperimmune Product Sales Price by Application (2021-2026) & (US$/unit) Table 222. SAMEA Human Plasma-derived Hyperimmune Product Sales Price by Application (2027-2032) & (US$/unit) Table 223. SAMEA Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 224. SAMEA Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 225. SAMEA Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 226. SAMEA Human Plasma-derived Hyperimmune Product Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 227. SAMEA Human Plasma-derived Hyperimmune Product Sales by Country (2021-2026) & (k units) Table 228. SAMEA Human Plasma-derived Hyperimmune Product Sales by Country (2027-2032) & (k units) Table 229. SAMEA Human Plasma-derived Hyperimmune Product Sales Price by Country (2021-2026) & (US$/unit) Table 230. SAMEA Human Plasma-derived Hyperimmune Product Sales Price by Country (2027-2032) & (US$/unit) Table 231. Brazil Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 232. Argentina Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 233. Chile Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 234. Colombia Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 235. Peru Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 236. Saudi Arabia Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 237. Israel Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 238. UAE Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 239. Turkey Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 240. Iran Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 241. Egypt Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Table 242. Key Raw Materials Table 243. Raw Materials Key Suppliers Table 244. Human Plasma-derived Hyperimmune Product Distributors List Table 245. Human Plasma-derived Hyperimmune Product Customers List Table 246. Research Programs/Design for This Report Table 247. Authors List of This Report Table 248. Secondary Sources Table 249. Primary Sources List of Figures Figure 1. Human Plasma-derived Hyperimmune Product Image Figure 2. Global Human Plasma-derived Hyperimmune Product Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Plasma-derived Hyperimmune Product Market Size Share 2021 VS 2025 VS 2032 Figure 4. Rho(D) Immunoglobulins Image Figure 5. Rabies Immunoglobulins Image Figure 6. Tetanus Immunoglobulins Image Figure 7. Hepatitis B Immunoglobulins Image Figure 8. Other Image Figure 9. Global Human Plasma-derived Hyperimmune Product Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Human Plasma-derived Hyperimmune Product Market Size Share 2021 VS 2025 VS 2032 Figure 11. Government Institution Image Figure 12. Private Sector Image Figure 13. Others Image Figure 14. Global Human Plasma-derived Hyperimmune Product Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Figure 16. Global Human Plasma-derived Hyperimmune Product Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Region (2021-2032) Figure 19. Global Human Plasma-derived Hyperimmune Product Sales (2021-2032) & (k units) Figure 20. Global Human Plasma-derived Hyperimmune Product Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 21. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Human Plasma-derived Hyperimmune Product Sales YoY (2021-2032) & (k units) Figure 23. Europe Human Plasma-derived Hyperimmune Product Sales YoY (2021-2032) & (k units) Figure 24. China Human Plasma-derived Hyperimmune Product Sales YoY (2021-2032) & (k units) Figure 25. Asia (Excluding China) Human Plasma-derived Hyperimmune Product Sales YoY (2021-2032) & (k units) Figure 26. South America, Middle East and Africa Human Plasma-derived Hyperimmune Product Sales YoY (2021-2032) & (k units) Figure 27. Global Human Plasma-derived Hyperimmune Product Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Human Plasma-derived Hyperimmune Product Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Human Plasma-derived Hyperimmune Product Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Type (2021-2032) Figure 33. Global Human Plasma-derived Hyperimmune Product Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 34. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2021-2032) Figure 36. Global Human Plasma-derived Hyperimmune Product Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Application (2021-2032) Figure 39. Global Human Plasma-derived Hyperimmune Product Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 40. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2021-2032) Figure 42. North America Human Plasma-derived Hyperimmune Product Revenue Share by Type (2021-2032) Figure 43. North America Human Plasma-derived Hyperimmune Product Sales Share by Type (2021-2032) Figure 44. North America Human Plasma-derived Hyperimmune Product Revenue Share by Application (2021-2032) Figure 45. North America Human Plasma-derived Hyperimmune Product Sales Share by Application (2021-2032) Figure 46. North America Human Plasma-derived Hyperimmune Product Revenue Share by Country (2021-2032) Figure 47. North America Human Plasma-derived Hyperimmune Product Sales Share by Country (2021-2032) Figure 48. Europe Human Plasma-derived Hyperimmune Product Revenue Share by Type (2021-2032) Figure 49. Europe Human Plasma-derived Hyperimmune Product Sales Share by Type (2021-2032) Figure 50. Europe Human Plasma-derived Hyperimmune Product Revenue Share by Application (2021-2032) Figure 51. Europe Human Plasma-derived Hyperimmune Product Sales Share by Application (2021-2032) Figure 52. Europe Human Plasma-derived Hyperimmune Product Revenue Share by Country (2021-2032) Figure 53. Europe Human Plasma-derived Hyperimmune Product Sales Share by Country (2021-2032) Figure 54. China Human Plasma-derived Hyperimmune Product Revenue Share by Type (2021-2032) Figure 55. China Human Plasma-derived Hyperimmune Product Sales Share by Type (2021-2032) Figure 56. China Human Plasma-derived Hyperimmune Product Revenue Share by Application (2021-2032) Figure 57. China Human Plasma-derived Hyperimmune Product Sales Share by Application (2021-2032) Figure 58. Asia Human Plasma-derived Hyperimmune Product Revenue Share by Type (2021-2032) Figure 59. Asia Human Plasma-derived Hyperimmune Product Sales Share by Type (2021-2032) Figure 60. Asia Human Plasma-derived Hyperimmune Product Revenue Share by Application (2021-2032) Figure 61. Asia Human Plasma-derived Hyperimmune Product Sales Share by Application (2021-2032) Figure 62. Asia Human Plasma-derived Hyperimmune Product Revenue Share by Country (2021-2032) Figure 63. Asia Human Plasma-derived Hyperimmune Product Sales Share by Country (2021-2032) Figure 64. SAMEA Human Plasma-derived Hyperimmune Product Revenue Share by Type (2021-2032) Figure 65. SAMEA Human Plasma-derived Hyperimmune Product Sales Share by Type (2021-2032) Figure 66. SAMEA Human Plasma-derived Hyperimmune Product Revenue Share by Application (2021-2032) Figure 67. SAMEA Human Plasma-derived Hyperimmune Product Sales Share by Application (2021-2032) Figure 68. SAMEA Human Plasma-derived Hyperimmune Product Revenue Share by Country (2021-2032) Figure 69. SAMEA Human Plasma-derived Hyperimmune Product Sales Share by Country (2021-2032) Figure 70. Human Plasma-derived Hyperimmune Product Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Human Plasma-derived Hyperimmune Product Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Rho(D) Immunoglobulins
  • Rabies Immunoglobulins
  • Tetanus Immunoglobulins
  • Hepatitis B Immunoglobulins
  • Other
Applications
  • Government Institution
  • Private Sector
  • Others
Companies covered
  • Sichuan Yuanda Shuyang
  • Shanghai RAAS
  • Grifols
  • Hualan Bio
  • Kedrion
  • Kamada
  • Emergent (Cangene)
  • CSL Behring
  • CNBG
  • CBPO
  • Biotest
  • ADMA Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Human Plasma-derived Hyperimmune Product Market by Type
  3. 1.2.1 Global Human Plasma-derived Hyperimmune Product Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Rho(D) Immunoglobulins
  5. 1.2.3 Rabies Immunoglobulins
  6. 1.2.4 Tetanus Immunoglobulins
  7. 1.2.5 Hepatitis B Immunoglobulins
  8. 1.2.6 Other
  9. 1.3 Human Plasma-derived Hyperimmune Product Market by Application
  10. 1.3.1 Global Human Plasma-derived Hyperimmune Product Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Government Institution
  12. 1.3.3 Private Sector
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Human Plasma-derived Hyperimmune Product Market Dynamics
  1. 2.1 Human Plasma-derived Hyperimmune Product Industry Trends
  2. 2.2 Human Plasma-derived Hyperimmune Product Industry Drivers
  3. 2.3 Human Plasma-derived Hyperimmune Product Industry Opportunities and Challenges
  4. 2.4 Human Plasma-derived Hyperimmune Product Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Human Plasma-derived Hyperimmune Product Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Human Plasma-derived Hyperimmune Product Revenue by Region
  3. 3.2.1 Global Human Plasma-derived Hyperimmune Product Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Human Plasma-derived Hyperimmune Product Revenue by Region (2021-2026)
  5. 3.2.3 Global Human Plasma-derived Hyperimmune Product Revenue by Region (2027-2032)
  6. 3.2.4 Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Human Plasma-derived Hyperimmune Product Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Human Plasma-derived Hyperimmune Product Sales by Region
  9. 3.4.1 Global Human Plasma-derived Hyperimmune Product Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Human Plasma-derived Hyperimmune Product Sales by Region (2021-2026)
  11. 3.4.3 Global Human Plasma-derived Hyperimmune Product Sales by Region (2027-2032)
  12. 3.4.4 Global Human Plasma-derived Hyperimmune Product Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Human Plasma-derived Hyperimmune Product Revenue by Manufacturers
  2. 4.1.1 Global Human Plasma-derived Hyperimmune Product Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Human Plasma-derived Hyperimmune Product Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Human Plasma-derived Hyperimmune Product Sales by Manufacturers
  6. 4.2.1 Global Human Plasma-derived Hyperimmune Product Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Human Plasma-derived Hyperimmune Product Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Human Plasma-derived Hyperimmune Product Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Human Plasma-derived Hyperimmune Product Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Human Plasma-derived Hyperimmune Product Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Human Plasma-derived Hyperimmune Product Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Human Plasma-derived Hyperimmune Product Manufacturers, Product Type & Application
  13. 4.7 Global Human Plasma-derived Hyperimmune Product Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Human Plasma-derived Hyperimmune Product Market CR5 and HHI
  16. 4.8.2 2025 Human Plasma-derived Hyperimmune Product Tier 1, Tier 2, and Tier 3
5 Human Plasma-derived Hyperimmune Product Market by Type
  1. 5.1 Global Human Plasma-derived Hyperimmune Product Revenue by Type
  2. 5.1.1 Global Human Plasma-derived Hyperimmune Product Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Human Plasma-derived Hyperimmune Product Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Human Plasma-derived Hyperimmune Product Sales by Type
  6. 5.2.1 Global Human Plasma-derived Hyperimmune Product Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Plasma-derived Hyperimmune Product Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2021-2032)
  9. 5.3 Global Human Plasma-derived Hyperimmune Product Price by Type
6 Human Plasma-derived Hyperimmune Product Market by Application
  1. 6.1 Global Human Plasma-derived Hyperimmune Product Revenue by Application
  2. 6.1.1 Global Human Plasma-derived Hyperimmune Product Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Human Plasma-derived Hyperimmune Product Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Human Plasma-derived Hyperimmune Product Sales by Application
  6. 6.2.1 Global Human Plasma-derived Hyperimmune Product Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Human Plasma-derived Hyperimmune Product Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2021-2032)
  9. 6.3 Global Human Plasma-derived Hyperimmune Product Price by Application
7 Company Profiles
  1. 7.1 Sichuan Yuanda Shuyang
  2. 7.1.1 Sichuan Yuanda Shuyang Company Information
  3. 7.1.2 Sichuan Yuanda Shuyang Business Overview
  4. 7.1.3 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product Portfolio
  6. 7.1.5 Sichuan Yuanda Shuyang Recent Developments
  7. 7.2 Shanghai RAAS
  8. 7.2.1 Shanghai RAAS Company Information
  9. 7.2.2 Shanghai RAAS Business Overview
  10. 7.2.3 Shanghai RAAS Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Shanghai RAAS Human Plasma-derived Hyperimmune Product Product Portfolio
  12. 7.2.5 Shanghai RAAS Recent Developments
  13. 7.3 Grifols
  14. 7.3.1 Grifols Company Information
  15. 7.3.2 Grifols Business Overview
  16. 7.3.3 Grifols Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Grifols Human Plasma-derived Hyperimmune Product Product Portfolio
  18. 7.3.5 Grifols Recent Developments
  19. 7.4 Hualan Bio
  20. 7.4.1 Hualan Bio Company Information
  21. 7.4.2 Hualan Bio Business Overview
  22. 7.4.3 Hualan Bio Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Hualan Bio Human Plasma-derived Hyperimmune Product Product Portfolio
  24. 7.4.5 Hualan Bio Recent Developments
  25. 7.5 Kedrion
  26. 7.5.1 Kedrion Company Information
  27. 7.5.2 Kedrion Business Overview
  28. 7.5.3 Kedrion Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Kedrion Human Plasma-derived Hyperimmune Product Product Portfolio
  30. 7.5.5 Kedrion Recent Developments
  31. 7.6 Kamada
  32. 7.6.1 Kamada Company Information
  33. 7.6.2 Kamada Business Overview
  34. 7.6.3 Kamada Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Kamada Human Plasma-derived Hyperimmune Product Product Portfolio
  36. 7.6.5 Kamada Recent Developments
  37. 7.7 Emergent (Cangene)
  38. 7.7.1 Emergent (Cangene) Company Information
  39. 7.7.2 Emergent (Cangene) Business Overview
  40. 7.7.3 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product Portfolio
  42. 7.7.5 Emergent (Cangene) Recent Developments
  43. 7.8 CSL Behring
  44. 7.8.1 CSL Behring Company Information
  45. 7.8.2 CSL Behring Business Overview
  46. 7.8.3 CSL Behring Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 CSL Behring Human Plasma-derived Hyperimmune Product Product Portfolio
  48. 7.8.5 CSL Behring Recent Developments
  49. 7.9 CNBG
  50. 7.9.1 CNBG Company Information
  51. 7.9.2 CNBG Business Overview
  52. 7.9.3 CNBG Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 CNBG Human Plasma-derived Hyperimmune Product Product Portfolio
  54. 7.9.5 CNBG Recent Developments
  55. 7.10 CBPO
  56. 7.10.1 CBPO Company Information
  57. 7.10.2 CBPO Business Overview
  58. 7.10.3 CBPO Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 CBPO Human Plasma-derived Hyperimmune Product Product Portfolio
  60. 7.10.5 CBPO Recent Developments
  61. 7.11 Biotest
  62. 7.11.1 Biotest Company Information
  63. 7.11.2 Biotest Business Overview
  64. 7.11.3 Biotest Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Biotest Human Plasma-derived Hyperimmune Product Product Portfolio
  66. 7.11.5 Biotest Recent Developments
  67. 7.12 ADMA Biologics
  68. 7.12.1 ADMA Biologics Company Information
  69. 7.12.2 ADMA Biologics Business Overview
  70. 7.12.3 ADMA Biologics Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 ADMA Biologics Human Plasma-derived Hyperimmune Product Product Portfolio
  72. 7.12.5 ADMA Biologics Recent Developments
8 North America
  1. 8.1 North America Human Plasma-derived Hyperimmune Product Market Size by Type
  2. 8.1.1 North America Human Plasma-derived Hyperimmune Product Revenue by Type (2021-2032)
  3. 8.1.2 North America Human Plasma-derived Hyperimmune Product Sales by Type (2021-2032)
  4. 8.1.3 North America Human Plasma-derived Hyperimmune Product Price by Type (2021-2032)
  5. 8.2 North America Human Plasma-derived Hyperimmune Product Market Size by Application
  6. 8.2.1 North America Human Plasma-derived Hyperimmune Product Revenue by Application (2021-2032)
  7. 8.2.2 North America Human Plasma-derived Hyperimmune Product Sales by Application (2021-2032)
  8. 8.2.3 North America Human Plasma-derived Hyperimmune Product Price by Application (2021-2032)
  9. 8.3 North America Human Plasma-derived Hyperimmune Product Market Size by Country
  10. 8.3.1 North America Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Human Plasma-derived Hyperimmune Product Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Human Plasma-derived Hyperimmune Product Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Human Plasma-derived Hyperimmune Product Market Size by Type
  2. 9.1.1 Europe Human Plasma-derived Hyperimmune Product Revenue by Type (2021-2032)
  3. 9.1.2 Europe Human Plasma-derived Hyperimmune Product Sales by Type (2021-2032)
  4. 9.1.3 Europe Human Plasma-derived Hyperimmune Product Price by Type (2021-2032)
  5. 9.2 Europe Human Plasma-derived Hyperimmune Product Market Size by Application
  6. 9.2.1 Europe Human Plasma-derived Hyperimmune Product Revenue by Application (2021-2032)
  7. 9.2.2 Europe Human Plasma-derived Hyperimmune Product Sales by Application (2021-2032)
  8. 9.2.3 Europe Human Plasma-derived Hyperimmune Product Price by Application (2021-2032)
  9. 9.3 Europe Human Plasma-derived Hyperimmune Product Market Size by Country
  10. 9.3.1 Europe Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Human Plasma-derived Hyperimmune Product Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Human Plasma-derived Hyperimmune Product Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Human Plasma-derived Hyperimmune Product Market Size by Type
  2. 10.1.1 China Human Plasma-derived Hyperimmune Product Revenue by Type (2021-2032)
  3. 10.1.2 China Human Plasma-derived Hyperimmune Product Sales by Type (2021-2032)
  4. 10.1.3 China Human Plasma-derived Hyperimmune Product Price by Type (2021-2032)
  5. 10.2 China Human Plasma-derived Hyperimmune Product Market Size by Application
  6. 10.2.1 China Human Plasma-derived Hyperimmune Product Revenue by Application (2021-2032)
  7. 10.2.2 China Human Plasma-derived Hyperimmune Product Sales by Application (2021-2032)
  8. 10.2.3 China Human Plasma-derived Hyperimmune Product Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Human Plasma-derived Hyperimmune Product Market Size by Type
  2. 11.1.1 Asia Human Plasma-derived Hyperimmune Product Revenue by Type (2021-2032)
  3. 11.1.2 Asia Human Plasma-derived Hyperimmune Product Sales by Type (2021-2032)
  4. 11.1.3 Asia Human Plasma-derived Hyperimmune Product Price by Type (2021-2032)
  5. 11.2 Asia Human Plasma-derived Hyperimmune Product Market Size by Application
  6. 11.2.1 Asia Human Plasma-derived Hyperimmune Product Revenue by Application (2021-2032)
  7. 11.2.2 Asia Human Plasma-derived Hyperimmune Product Sales by Application (2021-2032)
  8. 11.2.3 Asia Human Plasma-derived Hyperimmune Product Price by Application (2021-2032)
  9. 11.3 Asia Human Plasma-derived Hyperimmune Product Market Size by Country
  10. 11.3.1 Asia Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Human Plasma-derived Hyperimmune Product Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Human Plasma-derived Hyperimmune Product Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Human Plasma-derived Hyperimmune Product Market Size by Type
  2. 12.1.1 SAMEA Human Plasma-derived Hyperimmune Product Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Human Plasma-derived Hyperimmune Product Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Human Plasma-derived Hyperimmune Product Price by Type (2021-2032)
  5. 12.2 SAMEA Human Plasma-derived Hyperimmune Product Market Size by Application
  6. 12.2.1 SAMEA Human Plasma-derived Hyperimmune Product Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Human Plasma-derived Hyperimmune Product Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Human Plasma-derived Hyperimmune Product Price by Application (2021-2032)
  9. 12.3 SAMEA Human Plasma-derived Hyperimmune Product Market Size by Country
  10. 12.3.1 SAMEA Human Plasma-derived Hyperimmune Product Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Human Plasma-derived Hyperimmune Product Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Human Plasma-derived Hyperimmune Product Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Human Plasma-derived Hyperimmune Product Value Chain Analysis
  2. 13.1.1 Human Plasma-derived Hyperimmune Product Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Human Plasma-derived Hyperimmune Product Production Mode & Process
  6. 13.2 Human Plasma-derived Hyperimmune Product Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Human Plasma-derived Hyperimmune Product Distributors
  9. 13.2.3 Human Plasma-derived Hyperimmune Product Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst